1. Home
  2. PBFS vs ALLO Comparison

PBFS vs ALLO Comparison

Compare PBFS & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pioneer Bancorp Inc.

PBFS

Pioneer Bancorp Inc.

N/A

Current Price

$17.41

Market Cap

440.6M

Sector

Finance

ML Signal

N/A

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

N/A

Current Price

$0.63

Market Cap

452.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PBFS
ALLO
Founded
1889
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
440.6M
452.6M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
PBFS
ALLO
Price
$17.41
$0.63
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $9.00
AVG Volume (30 Days)
10.2K
★ 11.4M
Earning Date
10-30-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 36.07
34.09
EPS
★ 0.36
N/A
Revenue
★ $15,814,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$180.53
P/E Ratio
$48.83
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$13.05
$0.65
52 Week High
$19.91
$4.46

Technical Indicators

Market Signals
Indicator
PBFS
ALLO
Relative Strength Index (RSI) 36.35 17.76
Support Level $16.80 N/A
Resistance Level $18.09 $2.22
Average True Range (ATR) 0.50 0.09
MACD -0.12 -0.03
Stochastic Oscillator 0.00 0.05

Price Performance

Historical Comparison
PBFS
ALLO

About PBFS Pioneer Bancorp Inc.

Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Share on Social Networks: